Clinical Trial Highlights A systematic review published in eClinicalMedicine in November 2024 analyzed data from over 88,000 participants across multiple studies
If you haven't started a GLP-1 protocol at all, does it make sense to hold off
The figures above come from separate studies with different populations and designs
PIONEER 7 provides data supporting oral semaglutide use as add-on to background oral glucose-lowering agents to improve glycemic control
After the run-in period, patients with inadequate glycemic control (A1C 7.5% to 11%) were randomized 2:1 to the addition of either 100 mg of sitagliptin or placebo, administered once daily
[Cut to Alexandra, a CVS Pharmacist, 8 years.] Alexandra, speaking: For diabetes, weve definitely seen the benefit that it can have in controlling blood sugar and your A1C